Babson, BD Partnership to Advance Diagnostic Blood Collection in New Care Settings
Babson Diagnostics and BD announced the expansion of a strategic partnership to move blood sample collection into new care settings.
Babson Diagnostics and BD announced the expansion of a strategic partnership to move blood sample collection into new care settings.
The AUR87A trial will involve 16 hospitals across Europe and the United States, making it the largest-ever prospective multicenter study of a diagnostic for the detection of recurrence after surgery in clear cell renal cell carcinoma.
ClearLight will combine the new Crystal technology with its Clarity automated lipid-clearing platform.
The test helps clinicians to determine whether a patient with metastatic castration-resistant prostate cancer will benefit most from taxane chemotherapy or androgen-directed therapeutics.
Read MoreCertification of the Elio Plasma Resolve liquid biopsy panel will make available a local, noninvasive, next-generation sequencing solution in Europe.
Read MoreThe liquid biopsy may enable clinical researchers to better understand tumor biology, particularly in early-stage disease.
Read MoreUsing the kit, clinicians can accurately and reproducibly monitor residual disease in patients with chronic myeloid leukemia, even at low levels.
Read MoreTogether, Precipio and PerkinElmer can provide a simple, reliable, automated cell-free DNA analysis workflow alongside a cutting-edge mutation enrichment technology, ICE COLD PCR, that will enable laboratories to efficiently use these technologies to support liquid biopsy testing.
Read MoreWith three NCI grants, BioFluidica is investigating chip-based liquid biopsy technologies for the detection of cancer and related genetic variants.
Read MoreThe 25-gauge biopsy needle completes the company’s product line, with expanded FDA indications for both fine needle aspiration and fine needle biopsy.
Read MoreThe draft LCD permits coverage for the use of Decipher among men with very low and low risk of prostate cancer according to National Comprehensive Cancer Network guidelines.
Read MoreThis is a companion article to the feature “Reducing the Diagnostic Odyssey.”
Read MoreThe company anticipates a $10 million annual European market, with $1 million in annual addressable sales potential from its local partner it Italy.
Read MoreAs more and more tests are granted waived complexity status, clinical laboratorians may have some concerns about whether such tests are truly comparable to those performed in a CLIA-accredited facility by trained professionals.
Read MoreAt the recent San Antonio Breast Cancer Symposium, researchers from the University of Southern California’s Norris Comprehensive Cancer Center presented results of extensive work with the Parsortix system from Angle.
Read MoreThe medium’s formula is designed to improve post-thaw performance and reduce the costs of freezing sperm.
Read MoreThis month’s issue features anatomic and digital pathology technologies from such companies as BioGenex, Indica Labs, and MicroDimensions.
Read MoreBlood-based genomic tests are improving treatment decision and start times.
Read More